Short Stature Guidelines

Updated: Feb 23, 2017
  • Author: Sunil Kumar Sinha, MD; Chief Editor: Robert P Hoffman, MD  more...
  • Print
Guidelines

Guidelines Summary

A 2016 update to 2003 guidelines for GH and insulinlike growth factor-I treatment in children and adolescents with GH deficiency, idiopathic short stature, or primary insulinlike growth factor-I deficiency, from the Pediatric Endocrine Society, suggests the use of “a shared decision-making approach to pursuing GH treatment for a child with” idiopathic short stature. The update also states that the “decision can be made on a case-by-case basis after assessment of physical and psychological burdens, and discussion of risks and benefits,” and recommends that GH therapy not be used routinely in every child with a height standard deviation score at or below -2.25. It also suggests that, due to response overlap between dosing groups, the GH dose be initiated at 0.24 mg/kg/wk, “with some patients requiring up to 0.47 mg/kg/week.” [17]